Avirulent strains of group A streptococci readily activate the complement system in normal human serum via the alternate complement pathway (ACP). Virulent M-positive group A streptococci are much less potent as activators of the ACP. The ability of M-positive streptococci to activate the ACP is enhanced by trypsinization or mild peptic digestion. The latter treatment removes the serologically active and antiphagocytic type-specific moieties of M protein, but retains the surface fuzzy layer. The phagocytosis of avirulent streptococci is markedly enhanced by preopsonization in serum chelated with Mg-ethylene glycol tetraacetic acid (classic complement pathway blocked) but not in serum devoid of heat-labile factors. These studies suggest that the function of M protein as a virulence factor may be mediated, at least in part, by its ability to retard interaction of ACP components with structures present on the streptococcal cell surface.
Group A streptococci (GrAS) are among the commonest bacterial pathogens of humans. They are of special interest because of their propensity to initiate delayed, nonsuppurative sequelae which are presumably mediated by immunological processes. The major virulence factor of GrAS is M protein, an antigen that is located on the bacterial cell surface and retards phagocytosis by mechanisms as yet unknown. The hyaluronate capsule of GrAS is a secondary virulence factor conferring additional resistance to phagocytosis (6) . Avirulent GrAS lacking both M protein and capsule are phagocytosed even in antibody-deficient sera, such as those of newborn colostrum-deprived piglets (13) , but such phagocytosis is markedly enhanced by the presence of thermolabile serum factors.
Recent studies have focused upon the interaction of GrAS somatic constituents and components of the complement system. Isolated streptococcal peptidoglycan, cell walls, cell membranes, and lipoteichoic acid have been reported to activate the alternate complement pathway (ACP) (3, 9, 15) . Little is known, however, concerning the interactions of whole, intact GrAS with the human complement system. In the present study I have demonstrated differences between virulent and avirulent GrAS in their ability to activate the ACP. Such differences appear to be due to the fact that M protein present in virulent strains retards interaction of ACP components with the streptococcal cell surface.
(This paper was presented in part at the Seventh International Symposium on Streptococci and Streptococcal Diseases, Oxford, England, September, 1978.) MATERIALS AND METHODS Bacteria and cultural conditions. GrAS of various serotypes were maintained on blood agar plates at 40C or in Todd-Hewitt broth at -90'C. They were tested regularly by M and T typing, capsule preparation, and growth in fresh human blood. M-positive strains were mouse-passed periodically to maintain optimal virulence. M protein content of hot-acid extracts of GrAS was monitored semiquantitatively by determining the highest dilution of the extract capable of producing precipitin reactions with specific antisera in capillary tubes. Before use in complement absorption or phagocytosis experiments, organisms were grown overnight in Todd-Hewitt broth and washed three times in normal saline or in phosphate-buffered saline (pH 7.2).
Complement activation. Serum was donated by five healthy volunteers, pooled, divided into 1.0-ml samples, and frozen immediately at -90'C. The serum pool was tested in the indirect bactericidal assay (14) against strains of each of the M types employed in the study to assure that it did not contain detectable amounts of type-specific antibody. Just before use, pooled serum samples were thawed and chelated with 10 mM ethylene glycol tetraacetic acid and MgCl2 (MgEGTA) . Sera chelated in this manner failed to lyse amboceptor-coated sheep erythrocytes, thus verifying blockage of the classic complement pathway (5 (Fig. 2) . Before pepsin treatment, absorption of pooled human serum with ultraviolet-killed M24 streptococci resulted in removal of approximately one-third of HC (Fig.  3) . Organisms whose surface had been altered by pepsin were capable of completely removing hemolytic activity.
The 
DISCUSSION
During the past few years there has been increasing interest in the interaction of bacterial and fungal organisms with the complement system (4, 7, 8, 10, 12) . Considerable variability has been observed both from species to species (7, 10) and within strains of the same species (4, 10) with regard to the ability of various microorganisms to activate the ACP as well as their specific requirements for opsonization.
Despite the fact that GrAS are known to undergo marked variations in phase of virulence (as measured by resistance to phagocytosis, M typability, and encapsulation) under differing in vivo and in vitro conditions, the possible effect of such variations on interactions with the human complement pathway has not heretofore been studied systematically. The serum absorption experiments presented here yield only semiquantitative results, because of both the nature of the assay system and the complicating factor of partial spontaneous ACP activation by Mg-EGTA. Nevertheless, they indicate that avirulent GrAS are more potent activators of the alternate pathway than are M-positive strains.
The nature of the cell wall substances which activate the ACP in whole, intact organisms is unknown. Considerable work has been done, however, with isolated somatic constituents of GrAS. Greenblatt et al. (9) , utilizing a kinetic assay of complement activation, determined that GrAS peptidoglycan was the most active material, on a weight basis, in activating the ACP, followed by cell walls, protoplast membranes, and whole cells. Peptidoglycan was more active than lipopolysaccharide from gram-negative bacilli or zymosan in ACP activation. The groupspecific carbohydrate showed no activity. Tauber et al. (15) , using a somewhat different assay system, found both GrAS cell walls and cell membranes to activate the ACP, but the latter did so more avidly. The ACP-activating factor in membranes was identified as a protein of molecular weight greater than 40,000 to 60,000 which activated complement by a properdin-independent mechanism. Lipoteichoic acid is also represented upon the cell surface, where it plays a critical role in binding of GrAS to mucosal surfaces (1). Fiedel and Jackson (3) have reported that lipoteichoic acid activates the alternate pathway, but this effect was dose dependent, occurred over a narrow range of lipoteichoic acid concentrations, and could not be detected at higher concentrations.
That the type-specific moiety of M protein is the substance that retards ACP activation is suggested by the known role of this antigen in virulence and by its location on the surface hairs. Moreover, treatments known to destroy M protein, e.g., proteolytic digestion by trypsin and pepsin, greatly enhanced the ability of virulent GrAS to activate the ACP. It is of course conceivable that the observed effects were due to derangement of some other surface structures) by the enzymatic treatment. However, the mild peptic digestion procedure employed is the gentlest known for removing surface M protein. As indicated above, this procedure resulted in the loss of serological and functional M-protein activity without causing gross morphological distortion of the organisms or denuding them of surface hairs. The other major virulence factor on the streptococcal surface is the hyaluronate capsule. A role for this structure in the complement interactions described here was not apparent, because hyaluronidase digestion of the capsule had no effect. Additional studies utilizing early-log-phase cultures might, however, cast further light upon this issue.
Interest in the potential biological significance of these findings is enhanced by the finding that M-negative GrAS are readily opsonized via the ACP. These findings are consistent with older studies indicating that heat-labile factors but not antibodies are required for phagocytosis of such avirulent organisms (13) . In contrast, Mpositive strains resist phagocytosis in the presence of fresh human blood unless type-specific anti-M antibodies are present (14) . Taken 
